AGTR2
ENSG00000180772
Target class
GPCR
Chromosome
X
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- ClinGen gene-disease validity
- Disputed
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- AGTR2
- Gene name
- Angiotensin II receptor type 2
- Gene symbol
- AGTR2
- Protein name
- Type-2 angiotensin II receptor (Angiotensin II type-2 receptor) (AT2 receptor)
- AT2
- MRX88
- Gene biotype
- Protein coding
- Gene family
- Angiotensin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 2
- Highest tissue expression
- 1.18
- Tissue specificity (Gini)
- 0.862
- Tissue specificity (tau)
- 0.935
- KEGG gene identifiers
- hsa:186
- Protein interaction confidence
- 0.8835
- Protein interaction partners
- 12
- R-HSA-375276
- R-HSA-418594
- End position
- 116174974
- Start position
- 116170744
- Chromosome
- X
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- PubMed 28379944
- PubMed 29967536
- PubMed 31899086
- PubMed 32669569
- Tissue specificity (tau)
- 0.934762
- Expression inequality (Gini)
- 0.861569
Expression in transcripts per million
- Cervix - Endocervix
- 1.18
- Lung
- 1.12
- Fallopian Tube
- 0.84
- Brain - Cerebellum
- 0.46
- Uterus
- 0.38
Expression in transcripts per million
- Cervix - Endocervix1.18
- Lung1.12
- Fallopian Tube0.84
- Brain - Cerebellum0.46
- Uterus0.38
- Cervix - Ectocervix0.21
- Heart - Atrial Appendage0.19
- Colon - Sigmoid0.15
- Artery - Aorta0.15
- Adrenal Gland0.12
- Brain - Cerebellar Hemisphere0.11
- Artery - Coronary0.07
- Pancreas0.06
- Heart - Left Ventricle0.06
- Cells - EBV-transformed lymphocytes0.05
- Adipose - Visceral (Omentum)0.05
- Colon - Transverse0.03
- Kidney - Medulla0.03
- Nerve - Tibial0
- Vagina0
- Cells - Cultured fibroblasts0
- Testis0
- Stomach0
- Bladder0
- Pituitary0
And 29 more, listed on the interactive page.
- GO:0001974
- GO:0007166
- GO:0007186
- GO:0008217
- GO:0030308
- GO:0038060
- GO:0042311
- GO:0051387
- GO:2001238
Cellular components
- GO:0005886
- GO:0004945
- GO:0005515
- GO:0048019
decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
Biological samples
- renal
PubMed 28216264hypocalvaria
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: hypocalvaria
Biological samples
- renal
PubMed 28216264oligoamnios
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: oligoamnios
Biological samples
- renal
PubMed 28216264increased urine excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urine excretion
Biological samples
- renal
PubMed 28216264decreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: decreased blood pressure
Biological samples
- renal
PubMed 28216264pulmonary hypoplasia
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: pulmonary hypoplasia
Biological samples
- renal
PubMed 28216264respiratory distress syndrome
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: respiratory distress syndrome
Biological samples
- renal
PubMed 28216264intrauterine growth retardation
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: intrauterine growth retardation
Biological samples
- renal
PubMed 28216264death
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: death
Biological samples
- renal
PubMed 28216264increased urinary sodium excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urinary sodium excretion
Biological samples
- renal
PubMed 28216264cerebral complications
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: cerebral complications
Biological samples
- renal
PubMed 28216264limb defects
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: limb defects
Biological samples
- renal
PubMed 28216264persistent patent ductus arteriosus
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: persistent patent ductus arteriosus
Biological samples
- renal
PubMed 28216264renal failure
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: renal failure
Biological samples
- renal
PubMed 28216264
Related records
Trials (86)
- : Vascular Function in Health and Disease
- A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome
- A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
- A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock
- A Study of LJPC-501 in Pediatric Patients With Hypotension
- A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
- A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
- A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
- Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
- Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects
- ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)
- Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients
- Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients
- Angiotensin 1-7 as a Therapy in the Treatment of COVID-19
- Angiotensin 1-7 in Obesity Hypertension
- Angiotensin 2 for AKI After OLT
- Angiotensin 2 for Hepatorenal Syndrome
- Angiotensin II for Distributive Shock
- Angiotensin II for Septic Shock Treatment
- Angiotensin II in General Anesthesia
Drugs (4)
- Angiotensin II
- Buloxibutid
- Olodanrigan Angiotensin II type 2 (AT-2) receptor antagonist
- Talfirastide